Centro di Riferimento Oncologico - CRO Aviano, ITALY FP6 - LIFE SCIENCE, GENOMICS AND BIOTECHNOLOGY FOR HEALTH  VITAL Development of optimized recombinant.

Slides:

Advertisements

Similar presentations

CEACHRUCNRSCPUINRAINRIAINSERMINSTITUT PASTEURIRD ARIISEFSINERISINSTITUT CURIEINSTITUT MINES-TELECOMUNICANCERIRBAIRSNCIRADFONDATION MERIEUX 1 ITMO Cancer.

Advertisements

EU support for Health Research: from FP6 to FP7

AVV February 2005 Support of the European Union to Research on Rare Diseases Dr Alain Vanvossel European Commission Research Directorate General Health.

1. 2 Key Applications of Genetic and Genomic Testing (slide 1 of 2) Diagnosis of Disease: Whereby genetic or genomic tests are used to screen a patient.

Retreat Topics iPSC Opportunities in NIAMS Diseases Science Management Forum: Leveraging and Strategic Funding Collaborations Atopic Dermatitis Advancing.

Clinical trials in Europe Emma Greenwood, Policy Manager Thursday 23 rd February.

Combating major diseases Gender aspects in research Gender aspects in research have a particular relevance to this theme as risk factors, biological mechanisms,

Michael Birrer, PI, Director, Gynecologic Medical Oncology, MGH Lari Wenzel, Co-PI, Prof. of Medicine, University of California, Irvine

1 Biomedical Sciences Public and Environmental Health Regenerative Medicine Translational Research.

E-Rare: Networking research programmes on rare diseases in Europe GIS-Institut des Maladies Rares (Paris, France) E-Rare Coordination Unit Support for.

21 October 2005 CNRS Building the Europe of Knowledge Octavi Quintana Trias, Director, European Commission Health Research Directorate, DG Research, Health.

Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.

Joakim Dillner, M.D. Professor Department of Laboratory Medicine Karolinska Institutet Sweden Karolinska Institutet.

DG ResearchEuropean Commission 1 FOOD QUALITY AND SAFETY DG RTD/E.2/JL - 8/8/2015 Development of new health-promoting foods Impact of Food on Health Scientific.

Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.

Research & Innovation Horizon societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 "Health, demographic change and wellbeing"

Rare Diseases Working Group Luzern, 24 September 2010.

Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.

05/09/2015www.ecrin.org1 European Clinical Research Infrastructures Network

High Resolution Studies within the European Cancer Information System Cooperation with EPAAC Riccardo Capocaccia Istituto Superiore di Sanità (ISS), Italy.

FP7 Health Work Programme MALTA 25 September 2008 Joana Namorado Horizontal Aspects & Coordination Directorate Health - Ethics/Gender DG Research – European.

The future prospects for clinical trials in Europe Richard Torbett Chief Economist, EFPIA.

Research on Digestive and Liver Diseases in FP7 Maria José Vidal-Ragout, MD, PhD Head of Unit, Medical Research Directorate-General for Research & Innovation.

The Sixth RTD Framework Programme Thematic Priority 1 Life Sciences: Genomics & Biotechnology for Health

BioSciencs Foro November 8th, New York Joaquin Guinea Chairman of BIOMADRID (

1 Charles Kessler European Commission Brussels FP7 2 nd call – April 2007 Health research in FP7 Innovative technologies for medicine Bialystok, 29 May.

NIAID Commitment to Influenza Research and Preparedness F. Gray Handley Associate Director for International Research Affairs National Institute of Allergy.

Recognition Of Team Science Faculty Appointments, Promotions and Titles at The Geisel School of Medicine at Dartmouth “Recognition by peers as an investigator.

Overview of EU medical genetics and population genomics research Milan Macek Prof. MD, DSc Charles University Prague Czech Republic St. Petersburg October.

Where to focus? Horizon 2020 'Health, demographic change and wellbeing' Open Info Day -Horizon 2020 'Health, demographic change and wellbeing' Brussels,

Adult-Onset Disease The Example of Colon Cancer Summer, 2012.

Precision Medicine A New Initiative. The Concept of Precision Medicine (PM) The prevention and treatment strategies that take individual variability into.

1 EU-funded health research activities against TB: FP6 actions and perspectives toward FP7 DG Research - European Commission 22 MARCH 2007.

The rise of digitized medicine disrupts current research and business models Jesper Tegnér Director of the Unit for Computational Medicine, Department.

September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.

The Value of Tissue Banks to Drug and Dx Developers Barbara L. Handelin, Ph.D. Conflicts of Interest, Privacy/Confidentiality, and Tissue Repositories:

Clinical trials in Framework programme 7 (FP7) EU Judita Kinkorová 2. Národní konference o doporučených postupech, Olomouc 13. listopadu 2010.

Male Reproductive Biology Group Home Page Faculty Bios Faculty Photos Group Photo Choudhry Lishko Smith Tran Faculty Specific Homepage Mission Statement.

2.1 Health in the 21 st Century Pg Objectives Gain an understanding of the cholera bacterium and how it spreads as well as efforts to stop the.

Prostate Cancer Research in Europe European Union Prostate Cancer Research Framework Program (FP) 6 FP6 funded projects in fiscal years 2004/2005 Total.

Public health research in Europe Mark McCarthy (University College London) Levels of health sciences molecules cells organs people populations Laboratory.

EU RTD + FP Discussion slides. EU RTD + FP Life sciences, genomics and biotechnology for health (one of 7 thematic priorities) (2514 Mill.

EURORDIS Eurordis Position on Research Priorities for Rare Diseases.

Dr. Manuel ROMARÍS Poverty-related Diseases European Commission Research DG Microbicides BXL, 07 October 2005 HIV/AIDS Research in the Sixth Framework.

The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.

Leading the Biomedical Revolution in Precision Health: How Stanford Medicine is Developing the Next Generation of Health Care Annual Stanford Medicine.

D4FF55A0-6B6F BF422A9BA9 Present by: Xiao Chen On December 7, 2015.

Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.

Promoting new competencies through gender mainstreaming: the example of life sciences and health research Ineke Klinge Genderstudies in health and health.

GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.

Full Proposal for the German Cancer Aid Priority Program 'Translational Oncology' (2st call) 2015 Lead Applicants: Prof. Dr. med. Magnus von Knebel Doeberitz.

NCI Division of Cancer Prevention Ongoing Activities at Frederick Facilities Presented By: Lori Minasian, M.D. Robert Shoemaker, Ph.D. October 1, 2015.

PRESENTAZIONE DEL WORK PROGRAMME 2013 HEALTH Gabriella Balestra BIOLAB - Dipartimento di Elettronica e Telecomunicazioni.

University of Pavia Dep. of Electrical, Computer and Biomedical Engineering Laboratory of Bioinformatics, Mathematical Modelling and Synthetic Biology.

European Funding Opportunities in Health University of the West of England 26 March 2010 Emma Carey

Medical and Health research in Norway – in brief Director Mari K. Nes 22 June 2006.

I farmaci innovativi in una prospettiva europea Giuseppe M.C. Rosano, MD, PhD Cardiovascular and Cell Sciences Research Institute, St George's University.

Project Summary Human biological samples including associated medical data, and biomolecular research tools are key resources in unravelling the interplay.

Research networks in movement disorders Joaquim Ferreira, MD, PhD Instituto de Medicina Molecular Faculdade de Medicina de Lisboa.

FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health

EU funding opportunities

From Bench to Clinical Applications: Money Talks

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Patient Involvement in the Development and Safe Use of

FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health

Group 3 Group 3 The “Omes” Precision Cancer Medicine

IMI – an opportunity to implement research for patients and with patients Catherine Brett European Parliament Interest Group on Allergy and Asthma

Horizon 2020 EarLy dEtection of cerVical cAncer in hard-to-reach populations: development and implementation of a new HPV test combining self-sampling.

Yeastern Biotech Co. Ltd.

Understanding the Role of Disability in MS Management

Presentation transcript:

Centro di Riferimento Oncologico - CRO Aviano, ITALY FP6 - LIFE SCIENCE, GENOMICS AND BIOTECHNOLOGY FOR HEALTH  VITAL Development of optimized recombinant idiotypic vaccines for subset-specific immunotherapy of B cell lymphomas ( Coordinator of a STREP, 3mln €)  CCPRB Cancer Control using Population-Based Registries and Biobanks (NoE, action of International Cooperation) FP5 - QUALITY OF LIFE  ERICBSBS Evaluation of the role of infections in cancer using biological specimen banks  TUBAFROST European Human Frozen Tumor Tissue Bank  ARCAGE Alcohol related cancers genetic susceptibility in Europe  ANTICANCER RETINOIDS Syntesys and mechanism of action of novel classes of retinoids and rexinoids with antineoplastic activities CRO Aviano

Centro di Riferimento Oncologico - CRO Aviano, ITALY CRO Aviano …looking for ongoing Proposals on topics: HEALTH 2011: SINGLE-STAGE: 1.4-4: High impact research initiative for better immunisation : High impact research initiative on the human epigenome : Epidemiology and aetiology of infection-related cancers HEALTH 2011: TWO-STAGE: 1.1-2: Genome-based biomarkers for patient stratification and pharmacogenomic strategies 1.4-2: Tools, technologies and devices for application in regenerative medicine : Investigator-driven clinical trials for therapeutic interventions in elderly populations … and other FP7 Health/calls, IMI calls, PHEA !

Centro di Riferimento Oncologico - CRO Aviano, ITALY CRO Aviano Contacts: Ermes Mestroni Scientific Direction R&D Projects – Technology …further information on our research activities: